Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
OBJECTIVE
Anti-TNF therapy has improved outcomes for patients with highly active RA. Less is known about its effectiveness in patients with lower disease activity. The aim of this analysis is to compare the response to anti-TNF therapy between RA patients with high (DAS28 > 5.1) and moderate (DAS28 > 3.2-5.1) disease activity.


METHODS
A total of 4687 anti-TNF and 344 DMARD patients with high disease activity despite treatment with two standard DMARDs (including MTX) and 224 anti-TNF- and 300 DMARD-treated patients with moderate disease activity were selected from the British Society For Rheumatology Biologics Register. Mean change in HAQ over the first 12 months of enrolment was compared first between anti-TNF-treated and untreated patients in each DAS28 group, and then between anti-TNF-treated patients in the moderate and high DAS28 groups, using doubly robust estimates, adjusting for age, gender, disease duration, baseline HAQ and DAS28 score, number of previous DMARDs and steroid use.


RESULTS
Compared with anti-TNF-untreated patients within each DAS group, treated patients were younger, had higher DAS28 and HAQ and had failed a higher number of previous DMARDs. The mean adjusted change in HAQ over 12 months was similar in anti-TNF-treated patients with moderate and high disease activity at baseline: moderate -0.26 (95% CI -0.35, -0.16), high -0.28 (95% CI -0.34, -0.23) and mean difference -0.03 (95% CI -0.14, 0.08).


CONCLUSIONS
Improvement in HAQ score 12 months after start of anti-TNF therapy was not dependent on baseline DAS28 scores, suggesting that substantial benefits may also be gained by treating those with moderately active disease despite standard DMARD therapy.
Hyrich
Kimme L
KL
ARC Epidemiology Unit, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK. kimme.hyrich@manchester.ac.uk
Deighton
Chris
C
Watson
Kath D
KD
Symmons
Deborah P M
DP
Lunt
Mark
M
D000367:Age Factors; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Biometrics. 2005 Dec;61(4):962-73
16401269
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Arthritis Rheum. 2003 Jun;48(6):1530-42
12794820
Clin Ther. 2000 Jan;22(1):128-39
10688396
Rheumatology (Oxford). 2006 Dec;45(12):1558-65
16705046
Rheumatology (Oxford). 2008 Apr;47(4):495-9
18316338
Rheumatology (Oxford). 2004 Dec;43(12):1504-7
15252215
Rheumatology (Oxford). 2008 Oct;47(10):1441-3
18596052
Arthritis Rheum. 2008 Jan 15;59(1):32-41
18163417
Ann Rheum Dis. 2007 Oct;66(10):1356-62
17293364
J Rheumatol. 1993 Mar;20(3):557-60
8478873
Ann Rheum Dis. 2004 May;63(5):508-16
15082480
Arthritis Rheum. 2005 Jan;52(1):36-41
15641055
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
Ann Rheum Dis. 2002 Apr;61(4):335-40
11874837
Lancet. 2004 Jul 17-23;364(9430):263-9
15262104
Arthritis Res Ther. 2006;8(3):R66
16600016
Health Technol Assess. 2004 Mar;8(11):iii, 1-91
14982655
Arthritis Rheum. 2005 Nov;52(11):3381-90
16258899
Arthritis Rheum. 1995 Jan;38(1):44-8
7818570
N Engl J Med. 2000 Nov 30;343(22):1594-602
11096166
Br J Rheumatol. 1986 May;25(2):206-9
3708236
Rheumatology (Oxford). 2005 Feb;44(2):157-63
15637039